1 | A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD) | Eisai Inc. | - Neurology Center of North Orange County, Fullerton
- Irvine Clinical Research Recruiting, Irvine
- Pacific Neuroscience Medical Group, Oxnard
View More
|
| 2 | GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease | Cortexyme Inc. | - ATP Clinical Research, Inc., Costa Mesa
- Standford University, Palo Alto
- CITRIALS, Santa Ana
View More
|
| 3 | A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
| Genentech, Inc. | - Pharmacology Research Institute, Los Alamitos
- Stanford University; Stanford Clinical Cancer Ctr, Palo Alto
View More
|
| 4 | SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study) | Seikagaku Corporation | - Coastal Pain and Spinal Diagnostics, Carlsbad, California, United States, 92009
- Pain Medicine Associates, Inc., Fountain Valley, California, United States, 92708
View More
|
| 5 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C)) | Biogen | - University of California San Diego Medical Center, La Jolla, California, United States, 92093-0949
- California Pacific Medical Center, San Francisco, California, United States, 94115
View More
|
| 6 | Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine | ACADIA Pharmaceuticals Inc.
| - Sutter Institute for Medical Research, Sacramento, California, United States, 95816
View More
|
| 7 | Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations | Cerevance Beta, Inc.
| - Collaborative Neuroscience Network, Long Beach, California, United States, 90806
- SC3 Research - Pasadena, Pasadena, California, United States, 91105
View More
|
| 8 | A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease | Neuraly, Inc. | - University of California, Irvine, California, United States, 92697
- SC3 Research, Pasadena, California, United States, 91105
View More
|
| 9 | A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment | Sutter Health | - Sutter Neuroscience Medical Group, Sacramento, California, United States, 95816
|
| 10 | Effects of Brain Beta Amyloid on Postoperative Cognition and 18F-AV-45-A14: Clinical Evaluation of Florbetapir F 18 (18F-AV-45) | University of California, San Francisco | - San Francisco VA Medical Center, San Francisco, California, United States, 94121
|
| 11 | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | Eisai Inc. | |
| 12 | Curcumin and Yoga Exercise Effects in Veterans at Risk for Alzheimer's Disease | VA Office of Research and Development | - VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States, 90073
|
| 13 | Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability | University of Minnesota | - UCSF, San Francisco, California, United States, 94158
|
| 14 | Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study) | Eli Lilly and Company | |
| 15 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients | Hoffmann-La Roche | |
| 16 | A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Avanir Pharmaceuticals | |
| 17 | A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease | AZTherapies, Inc. | |
| 18 | Long-Term Nicotine Treatment of Mild Cognitive Impairment | University of Southern California | |
| 19 | Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study | University of Southern California | - University of Southern California, Los Angeles, California, United States, 90032
|
| 20 | A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease | Stemedica Cell Technologies, Inc. | - John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States, 90404
|
| 21 | A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease | AbbVie | |
| 22 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) | Annovis Bio Inc. | - UCSD Alzheimer's Disease Research Center, La Jolla, California, United States, 92037
|
| 23 | Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US) | Eli Lilly and Company | - California Pharmaceutical Research Institute, Anaheim, California, United States, 92804
- Advanced Research Center, Anaheim, California, United States, 92805
|
| 24 | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | Eisai Co., Ltd. | - Facility #1, Colton, California, United States, 92324
|
| 25 | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | Eisai Co., Ltd. | |
| 26 | A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia | University of California, Irvine | - University of California, Irvine, Irvine, California, United States, 92697
- University of California, Los Angeles, Los Angeles, California, United States, 90095
|
| 27 | More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease | University of Colorado, Denver | - University of California, San Francisco, San Francisco, California, United States, 94143
|
| 28 | Escitalopram for Agitation in Alzheimer's Disease | JHSPH Center for Clinical Trials | |
| 29 | A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease | Adam Boxer | - University of California, San Diego, San Diego, California, United States, 92093
- University of California, San Francisco, San Francisco, California, United States, 94158
|
| 30 | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease | Genentech, Inc. | - California Clinical Trials, Glendale, California, United States, 91206
|
| 31 | Study of Non-Invasive Deep Brain Stimulation With Low Intensity Focused Ultrasound Pulse (LIFUP) for Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease (AD) | University of California, Los Angeles | - UCLA Longevity Center, Los Angeles, California, United States, 90095
|
| 32 | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease | Biogen | |
| 33 | Examining the Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance in Patients Undergoing Neuroimaging Evaluation for Cognitive Decline: A Double-blinded Placebo Controlled Expansion Study | University of California, Los Angeles | - University of California, Los Angeles, Los Angeles, California, United States, 90095
|
| 34 | Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease | Eli Lilly and Company | |
| 35 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Avanir Pharmaceuticals | |
| 36 | Examining the Impact of Photobiomodulation on Cognition, Behavior, and Biomarkers of Alzheimer's Disease | University of California, San Francisco | - VA Health Care System, San Francisco, California, United States, 94121
- UCSF Memory and Aging Center, San Francisco, California, United States, 94158
|
| 37 | Coaching for Cognition in Alzheimer's (COCOA) | Hoag Memorial Hospital Presbyterian | - Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States, 92663
|
| 38 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease | Hoffmann-La Roche | |
| 39 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease | Hoffmann-La Roche | - CITrials, Inc., Bellflower, California, United States, 90706
|
| 40 | Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment | TauRx Therapeutics Ltd | |
| 41 | A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers | University of California, Los Angeles | - University of California Los Angeles, Los Angeles, California, United States, 90095
- Veterans Affairs Greater Los Angeles Healthcare System, North Hills, California, United States, 91343
|
| 42 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease | AgeneBio | - Senior Clinical Trials, Inc., Laguna Hills, California, United States, 92653
|
| 43 | Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training | University of California, Los Angeles | - UCLA Semel Institute, Los Angeles, California, United States, 90095
|
| 44 | Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease | Eli Lilly and Company | |
| 45 | Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers: Inflammatory and Biological Aging Mechanisms | University of California, Los Angeles | - Cousins Center for Psychoneuroimmunology, UCLA Neuropsychiatric Institute, Los Angeles, California, United States, 90095
|
| 46 | A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type | Otsuka Pharmaceutical Development & Commercialization, Inc. | - For additional information regarding sites, contact 844-687-8522, Los Angeles, California, United States, 90036
|
| 47 | A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease | Biohaven Pharmaceuticals, Inc. | |
| 48 | The Delivery of Essential Fatty Acids to the Brain | University of Southern California | - USC Keck School of Medicine, Los Angeles, California, United States, 90033
|
| 49 | ADvance II: A 12-month Double-blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease | Functional Neuromodulation Ltd | - University of Southern California, Los Angeles, California, United States, 90033
|
| 50 | A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's Disease | Zhejiang Hisun Pharmaceutical Co. Ltd. | - Northern California Research, Sacramento, California, United States, 95821
- Pacific Research Network, Inc., San Diego, California, United States, 92103
|
| 51 | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease | AriBio Co., Ltd. | - Advanced Clinical Research, Inc., Banning, California, United States, 92220
- Northern California Research, Sacramento, California, United States, 95821
|
| 52 | Fall Detection and Prevention for Memory Care Through Real-time Artificial Intelligence Applied to Video: A Randomized Control Trial | SafelyYou | - SafelyYou, San Francisco, California, United States, 94107
|
| 53 | U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk | Wake Forest University Health Sciences | - Northern California, Sacramento, California, United States, 95616
|
| 54 | Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease | University of California, San Diego | - Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California, United States, 92103
|
| 55 | Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD) | Alzheimer's Disease Cooperative Study (ADCS) | - University of Southern California, Los Angeles, California, United States, 90033
- University of California, San Diego (UCSD), San Diego, California, United States, 92093
|
| 56 | An Extension Study of ABBV-8E12 in Early Alzheimer's Disease | AbbVie | |
| 57 | A Nonrandomized Evaluation of a Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's Dementia | University of California, Davis | - University of California Davis, Sacramento, California, United States, 95816
|
| 58 | Prevention of Alzheimer's Disease in Women: Risks and Benefits of Hormone Therapy -Continuation of: "The Kronos Early Estrogen Prevention Study (KEEPS)" Mayo Clinic IRB#2241-04-00 | Mayo Clinic | - University of California San Francisco, San Francisco, California, United States, 94158
|
| 59 | A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type | Renew Research, LLC | - Irvine Clinical Research, Irvine, California, United States, 92614
|
| 60 | Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: IV to IM Bridging Study | University of Arizona | - University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II, Los Angeles, California, United States, 90033
|
| 61 | A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease | Tetra Discovery Partners | - CiTrials, Inc., Bellflower, California, United States, 90709
|
| 62 | GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease | Cortexyme Inc. | |
| 63 | Developing and Evaluating In-Home Supportive Technology for Dementia Caregivers | University of California, Berkeley | - University of California, Berkeley, Berkeley, California, United States, 94720
- Los Angeles County, Los Angeles, California, United States, 90011
|
| 64 | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease | Genentech, Inc. | - Collaborative Neuroscience Network, Inc., Garden Grove, California, United States, 92845
- Pharmacology Research Institute, Los Alamitos, California, United States, 90720
|
| 65 | MRI and PET Biomarkers for Cognitive Decline in Older Adults | University of California, Irvine | - University of California, Irvine, Irvine, California, United States, 92697
|
| 66 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | Eisai Inc. | |
| 67 | Development of Novel Measures of Cognition and Function for Alzheimer's Disease Prevention Trials | New York State Psychiatric Institute | - University of Southern California, Los Angeles, California, United States, 90033
|
| 68 | Tau Imaging With JNJ067 | University of California, Berkeley | - University of California, Berkeley, Berkeley, California, United States, 94709
|
| 69 | Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age | Neuronascent, Inc. | - Parexel, International, Glendale, California, United States, 91206
|
| 70 | The PREVENTION Trial: Precision Recommendations for Environmental Variables, Exercise, Nutrition and Training Interventions to Optimize Neurocognition | John Wayne Cancer Institute | - Pacific Brain Health Center, Santa Monica, California, United States, 90404
|
| 71 | An Open-label Study to Investigate the Effectiveness of a LifeSeasons NeuroQ Supplement in Addition to Four Bredesen Recommended Lifestyle Changes to Improve Cognitive Function in Healthy Adults Who Have One or More Risk Factors for Cognitive Decline | LifeSeasons Inc. | - Kapoor Medical Center, Studio City, California, United States, 91604
|
| 72 | Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease | H. Lundbeck A/S | - California Clinical Trials Medical Group, Los Angeles, California, United States, 91206-4007
|
| 73 | Lymphatic System Health in Alzheimer's Disease | Neurological Associates of West Los Angeles | - Westwood Open MRI, Los Angeles, California, United States, 90024
- Neurological Associates of West Los Angeles, Santa Monica, California, United States, 90403
|
| 74 | Developing and Evaluating In-Home Supportive Technology for Caregivers of People With Dementia and Mild Cognitive Impairment | University of California, Berkeley | - University of California, Berkeley, Berkeley, California, United States, 94720
|
| 75 | Compensation Training to Improve Everyday Functioning of Older Adults With Mild Cognitive Impairment and Subjective Cognitive Complaints: The Digital Memory Notebook | University of California, Davis | - Alzheimer's Disease Center, University of California, Davis, Sacramento, California, United States, 95817
|
| 76 | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 | Biogen | - Neurology Center of North Orange County, Fullerton, California, United States, 92835
|
| 77 | The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias | Neurological Associates of West Los Angeles | - Neurological Associates of West LA, Santa Monica, California, United States, 90403
|
| 78 | Water-based Activity to Enhance Recall in Veterans: A Randomized Clinical Trial | VA Office of Research and Development | - VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States, 94304-1290
|
| 79 | An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease | Hoffmann-La Roche | - Pacific Research Network - PRN, San Diego, California, United States, 92103
- California Neuroscience Research Medical Group, Inc, Sherman Oaks, California, United States, 91403
|
| 80 | SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD | Vaccinex Inc. | - Pacific Research Network, Inc, San Diego, California, United States, 92103
|
| 81 | Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related Dementias | University of California, San Francisco | - University of California, San Francisco, San Francisco, California, United States, 94118
|
| 82 | Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease | Eli Lilly and Company | |
| 83 | A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease | Eli Lilly and Company | - Collaborative Neuroscience Network, Long Beach, California, United States, 90806
|
| 84 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Avanir Pharmaceuticals | - Clinical Research Site, San Diego, California, United States, 92128
|
| 85 | Virtual Patient Behavioral Response Training for Family Caregivers | Photozig, Inc. | - Photozig, Inc., Mountain View, California, United States, 94035-0128
|
| 86 | Feasibility of At-Home Telehealth Yoga for Treating Chronic Pain | Palo Alto Veterans Institute for Research | - VA Palo Alto Health Care System, Palo Alto, California, United States, 94304
|
| 87 | Caring Light Project for Caregivers of Individuals With Alzheimer's Disease | Photozig, Inc. | - Photozig, Inc., Mountain View, California, United States, 94035-0128
|
| 88 | Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies | AbbVie (prior sponsor, Abbott) | - The Research Ctr Southern CA /ID# 49928, Carlsbad, California, United States, 92011-4219
|
| 89 | The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry | Scripps Translational Science Institute | - Scripps Clinic, Torrey Pines, La Jolla, California, United States, 92037
- Scripps Translational Science Institute, La Jolla, California, United States, 92037
|
| 90 | The Parkinson's Progression Markers Initiative (PPMI) | Ken Marek, MD | |
| 91 | Molecular Analysis of Adult Human-derived Neural Stem Cells | NeuroGeneration | - Los Angeles Neurosurgical Institute, Los Angeles, California, United States, 90211
|
| 92 | Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives | 23andMe, Inc. | - Www.23Andme.Com/Pd, Mountain View, California, United States, 94043
|
| 93 | Parkinson's Foundation Quality Improvement Initiative | National Parkinson Foundation | - Parkinson's Institute and Clinical Center, Sunnyvale, California, United States, 94085
|
| 94 | Implantable Neurostimulator for the Treatment of Parkinson's Disease | Boston Scientific Corporation | - , Los Angeles, California, United States, 90048
- Boston Scientific Clinical Research Information Toll Free Number, Valencia, California, United States, 91355
|
| 95 | A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives | Sanguine Biosciences | - Sanguine Biosciences, Los Angeles, California, United States, 91403
|
| 96 | Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia | University of California, San Francisco | - UCSF Surgical Movement Disorders Center, San Francisco, California, United States, 94115
|
| 97 | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | Boston Scientific Corporation | - Boston Scientific Clinical Research Toll-Free Number, Valencia, California, United States, 91355
|
| 98 | A Feasibility Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System | InSightec | - Stanford University Medical Center, Stanford, California, United States, 94305
|
| 99 | Exercise Targeting Cognitive Impairment in Parkinson's Disease | University of Southern California | - University of Southern California, Los Angeles, California, United States, 90033-4606
|
| 100 | A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy | US WorldMeds LLC | - , Loma Linda, California, United States, 92354
|
| 101 | Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease | Stanford University | - Stanford Movement Disorders Center, Stanford, California, United States, 94305-5235
|
| 102 | Brain Health Registry | University of California, San Francisco | - BrainHealthRegistry.org, San Francisco, California, United States, 94143
|
| 103 | An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) | Sunovion | |
| 104 | An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study | AbbVie | - Parkinson's and Movement /ID# 161596, Fountain Valley, California, United States, 92708
|
| 105 | RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy | Lundbeck Northera Ltd. | |
| 106 | A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease | NeuroDerm Ltd. | |
| 107 | Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant. | Genzyme, a Sanofi Company | |
| 108 | Antigen Presentation and Lymphocyte Response in Parkinson's Disease | Columbia University | - University of California San Diego School of Medicine, La Jolla, California, United States, 92037
|
| 109 | A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease | Cedars-Sinai Medical Center | - Cedars Sinai Medical Center, Los Angeles, California, United States, 90048
|
| 110 | The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's Disease | Stanford University | - Stanford Movement Disorders Clinic, Stanford, California, United States, 94304
|
| 111 | Post Market Clinical Follow Up Evaluating the Infinity Deep Brain Stimulation Implantable Pulse Generator System | Abbott Medical Devices | - Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States, 94229
|
| 112 | Identification of Tear Biomarkers for Parkinson's Disease Patients | University of Southern California | - University of Southern California, Los Angeles, California, United States, 90033
|
| 113 | An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa | Neurocrine Biosciences | - University of California, San Francisco (UCSF), San Francisco, California, United States, 94143
|
| 114 | More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease | University of Colorado, Denver | - University of California, San Francisco, San Francisco, California, United States, 94143
|
| 115 | A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension | Hoffmann-La Roche | |
| 116 | Global Registry: ExAblate 4000 Transcranial MR Guided Focused Ultrasound (TcMRgFUS) of Neurological Disorders: | InSightec | - Stanford University, Stanford, California, United States, 94305
|
| 117 | Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's | University of California, San Francisco | - UCSF Surgical Movement Disorders Center, San Francisco, California, United States, 94115
|
| 118 | Management of Parkinson's Disease Psychosis in Actual Practice (The INSYTE Study) | ACADIA Pharmaceuticals Inc. | |
| 119 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease | Biogen | |
| 120 | A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System | InSightec | - Stanford University Medical Center, Stanford, California, United States, 94305
|
| 121 | A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER. | Pharma Two B Ltd. | |
| 122 | Cognitive Rehabilitation for Individuals With Parkinson's Disease and MCI | VA Office of Research and Development | - VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States, 92161
|
| 123 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Loma Linda University | - Loma Linda University Faculty Medical Offices - Neurology Clinic, Loma Linda, California, United States, 92354
|
| 124 | A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations | Neurocrine Biosciences | - UC Irvine, Irvine, California, United States, 92697
- UC Davis Health System, Sacramento, California, United States, 95817
|
| 125 | Microbiota Intervention to Change the Response of Parkinson's Disease | University of California, San Francisco | - University of California San Francisco, San Francisco, California, United States, 94115
|
| 126 | Closed Loop Deep Brain Stimulation in Parkinson's Disease and Dystonia (Activa RC+S) | University of California, San Francisco | - University of California at San Francisco, San Francisco, California, United States, 94115
|
| 127 | Invasive Approach to Model Human Cortex-Basal Ganglia Action-Regulating Networks | University of California, Los Angeles | - Nader Pouratian, Los Angeles, California, United States, 90095
|
| 128 | Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease | H. Lundbeck A/S | - California Clinical Trials Medical Group (CCTMG), Glendale, California, United States, 91206
|
| 129 | Effects of Osteopathic Manipulative Treatment (OMT) on Gait Biomechanics in Parkinson's Disease (OMT/PD) | University of California, San Diego | - University of California, San Diego, La Jolla, California, United States, 92093
|
| 130 | North American Prodromal Synucleinopathy Consortium | Washington University School of Medicine | - University of California Los Angeles, Los Angeles, California, United States, 90095
|
| 131 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease | Sun Pharma Advanced Research Company Limited | - Keck Hospital of USC, Los Angeles, California, United States, 90033
|
| 132 | Deep Brain Stimulation (DBS) Retrospective Outcomes Study | Boston Scientific Corporation | - Boston Scientific Clinical Research Information Toll Free Number, Valencia, California, United States, 91355
|
| 133 | A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations | Impax Laboratories, LLC | |
| 134 | A Multicenter, Prospective, Longitudinal, Digital Assessment Study of Disease Progression in Subjects With Early, Untreated Parkinson Disease | University of Rochester | - University of California San Francisco, San Francisco, California, United States, 94115
|
| 135 | An Observational, Long-Term Extension Study for Participants in Prior VY-AADC01 Clinical Studies | Neurocrine Biosciences | - University of California, San Francisco, San Francisco, California, United States, 94143
|
| 136 | Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status (APPRISE) | Global Kinetics Corporation | - Sutter Health, Sacramento, California, United States, 95816
- University of California, San Diego, California, United States, 92037
|
| 137 | A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure | Theravance Biopharma | |
| 138 | The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease | Michele Tagliati, MD | - Cedars Sinai Medical Center, Los Angeles, California, United States, 90048
|
| 139 | A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease | AbbVie | |
| 140 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET) | Enterin Inc. | |
| 141 | A Prospective, Randomized, Staggered-onset, Double Blinded, Sham-Controlled Study to Evaluate Peripheral Vibrotactile Coordinated Reset (CR) Stimulation for Parkinson's Disease | Casey H. Halpern | - Stanford University, Stanford, California, United States, 94305
|
| 142 | Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study | Centogene AG Rostock | - Pharmacology Research Institute, Encino, California, United States, 91316
|
| 143 | An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations | Impax Laboratories, LLC | |
| 144 | A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe) | Prilenia | |
| 145 | TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease | California Pacific Medical Center Research Institute | - Loma Linda University, Loma Linda, California, United States, 92350
|
| 146 | A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia. | Enterin Inc. | - Neuro Pain Medical Center, Fresno, California, United States, 93710
|
| 147 | Utilization of Target Ranges to Treat Patients With Parkinson's Disease by Objective Measurement Using the Personal KinetiGraph® (PKG®) Compared to Standard of Care Assessment (TARGET-PD)- A Randomized Controlled Trial | Global Kinetics Corporation | |
| 148 | Mindfulness Based Stress Reduction for Parkinson's Disease: A Longitudinal Study | VA Office of Research and Development | - VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States, 92161
|
| 149 | A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless) | NeuroDerm Ltd. | - The Research Center of Southern California, Carlsbad, California, United States, 92011
|
| 150 | Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback | Stanford University | - Stanford University, Stanford, California, United States, 94305
|
| 151 | Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's Disease | Parkinson's Foundation | - University of California San Diego (UCSD), La Jolla, California, United States, 92093
|
| 152 | Decision Making Among Older Adults: the AUTO Study | University of Colorado, Denver | - University of California, San Diego, La Jolla, California, United States, 92037
|
| 153 | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease | ProgenaBiome | - ProgenaBiome, Ventura, California, United States, 93003
|
| 154 | A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's Disease | Aptinyx | - Aptinyx Clinical Site, Fresno, California, United States, 93710
|
| 155 | Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease | Neuraly, Inc. | |
| 156 | A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine | ACADIA Pharmaceuticals Inc. | |
| 157 | Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease | Brain Neurotherapy Bio, Inc. | - University of California Irvine, Irvine, California, United States, 92697
- University of California San Francisco, San Francisco, California, United States, 94103
|
| 158 | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations | Cerevance Beta, Inc. | - Collaborative Neuroscience Network, LLC, Long Beach, California, United States, 90806
- SC3 Research - Pasadena, Pasadena, California, United States, 91105
|
| 159 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL) | Cerevel Therapeutics, LLC | - Fountain Valley, California, Fountain Valley, California, United States, 92708
|
| 160 | The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study | Cedars-Sinai Medical Center | - Cedars Sinai Medical Center, Los Angeles, California, United States, 90048
|
| 161 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial) | Cerevel Therapeutics, LLC | - Fresno, California, Fresno, California, United States, 93710
|
| 162 | The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias | Neurological Associates of West Los Angeles | - Neurological Associates of West LA, Santa Monica, California, United States, 90403
|
| 163 | Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3 | Northwestern University | - University of Southern California, Los Angeles, California, United States, 90007
|
| 164 | A Study to Analyze Features of Dysphonia and Tremor in PD Patients to Aid in the Development of an Accurate Diagnostic Tool for Early-Detection of PD | Goalspal LLC | - Goalspal LLC, Pleasanton, California, United States, 94566
|
| 165 | A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis | ACADIA Pharmaceuticals Inc. | - Neurology Center of North Orange County, Fullerton, California, United States, 92835
|
| 166 | A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson's Disease | Cerevel Therapeutics, LLC | - CNS Network, Long Beach, California, United States, 90806
|
| 167 | A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls | Takeda | - Collaborative Neuroscience Network, LLC, Torrance, California, United States, 90502
- Cedars Sinai Medical Center, West Hollywood, California, United States, 90048-1804
|
| 168 | A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components | Bukwang Pharmaceutical | - Bukwang Investigator site, Fountain Valley, California, United States, 92704
- Bukwang Investigator site, Fullerton, California, United States, 92835
|
| 169 | A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients | AbbVie | |
| 170 | Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related Dementias | University of California, San Francisco | - University of California, San Francisco, San Francisco, California, United States, 94118
|
| 171 | Mindfulness-based Cognitive Therapy for People With Parkinson's Disease and Caregivers | University of California, San Francisco | - University of California, San Francisco, San Francisco, California, United States, 94143
|
| 172 | An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment | Sage Therapeutics | - Sage Investigational Site, Long Beach, California, United States, 90806
|
| 173 | The Parkinson's Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort | Michael J. Fox Foundation for Parkinson's Research | |
| 174 | A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period | Enterin Inc. | - The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States, 92708
- SC3 Research - Pasadena, Pasadena, California, United States, 91105
|
| 175 | Subcortical-cortical Network Dynamics of Anesthesia and Consciousness | University of California, Los Angeles | - Nader Pouratian, Los Angeles, California, United States, 90095
|
| 176 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) | Cerevel Therapeutics, LLC | - Fountain Valley, California, Fountain Valley, California, United States, 92708
- Frenso, California, Fresno, California, United States, 93710
|
| 177 | Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy | Novartis Pharmaceuticals | |
| 178 | A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition. | University of California, Los Angeles | - University of California Los Angeles, Los Angeles, California, United States, 90095
|
| 179 | A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase | Novartis Pharmaceuticals | |
| 180 | A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives | Sanguine Biosciences | - Sanguine Biosciences, Los Angeles, California, United States, 91403
|
| 181 | A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis | Immune Response BioPharma, Inc. | - CRO, San Diego, California, United States, 92129
|
| 182 | A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination | Immune Response BioPharma, Inc. | - CRO, San Diego, California, United States, 92129
|
| 183 | A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis | Immune Response BioPharma, Inc. | - CRO, San Diego, California, United States, 92129
|
| 184 | Brain Health Registry | University of California, San Francisco | - BrainHealthRegistry.org, San Francisco, California, United States, 94143
|
| 185 | A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis | University of California, San Francisco | - University of California San Francisco, San Francisco, California, United States, 94158
|
| 186 | International Deprexis Trial in Multiple Sclerosis (IDEMS) - a Multicenter Randomized Controlled Trial | Charite University, Berlin, Germany | - Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
|
| 187 | Teriflunomide Pregnancy Outcome Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project | Sanofi | - Investigator, San Diego, California, United States, 92093
|
| 188 | A Pragmatic Trial to Evaluate the Intermediate-term Effects of Early, Aggressive Versus Escalation Therapy in People With Multiple Sclerosis | Johns Hopkins University | |
| 189 | An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis | Hoffmann-La Roche | - MS Center of California, Newport Beach, California, United States, 92663
- SC3 Research Group, Inc, Pasadena, California, United States, 91105
|
| 190 | Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis: A Phase 1b Clinical Trial to Evaluate Feasibility, Safety, Tolerability and Effects on Immune Function | University of California, San Francisco | - UCSF Multiple Sclerosis Center, San Francisco, California, United States, 94158
|
| 191 | Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study | Novartis Pharmaceuticals | |
| 192 | Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab). | University of Southern California | - University of Southern California, Department of Neurology, Los Angeles, California, United States, 90033
|
| 193 | An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | Novartis Pharmaceuticals | |
| 194 | A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic Control | University of California, San Francisco | - University of California San Francisco, San Francisco, California, United States, 94158
|
| 195 | Computerized Cognitive Training for Patients With Cognitive Deficits Due to Multiple Sclerosis: a Pilot Study | Riley Bove, MD | - Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, United States, 94158
|
| 196 | A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS | Brainstorm-Cell Therapeutics | - University of Southern California, Los Angeles, California, United States, 90033
- Stanford University School of Medicine, Redwood City, California, United States, 943063
|
| 197 | A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) | National Cancer Institute (NCI) | - Stanford Cancer Institute Palo Alto, Palo Alto, California, United States, 94304
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817
|
| 198 | Feasibility of the Multiple Sclerosis Performance Test for Assessment of Functional Performance Measures in Patients With Multiple Sclerosis | Biogen | - Research Site, Berkeley, California, United States, 94705
- Research Site, Los Angeles, California, United States, 90033-5310
|
| 199 | Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (MASTER-2) | EMD Serono Research & Development Institute, Inc. | |
| 200 | Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Injectable Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (CLICK-MS) | EMD Serono Research & Development Institute, Inc. | |
| 201 | An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension | Biogen | - Research Site, La Jolla, California, United States, 92024
|
| 202 | A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Delayed-Start Trial to Assess the Efficacy, Safety, and Tolerability of Bazedoxifene Acetate (BZA) as a Remyelinating Agent in Patients With Multiple Sclerosis | Riley Bove, MD | - Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, United States, 94158
|
| 203 | A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | Hoffmann-La Roche | - Arcadia Neurology Center, Arcadia, California, United States, 91006
|
| 204 | A Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS) | University of California, San Francisco | - University of California, San Francisco, San Francisco, California, United States, 94158
|
| 205 | A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI) | National Institute of Allergy and Infectious Diseases (NIAID) | - Stanford Multiple Sclerosis Center, Palo Alto, California, United States, 94304
|
| 206 | The Impact of a Planned 12-week Dosing Interruption of Natalizumab on Immune Cell Trafficking, Pharmacokinetic (PK)/Pharmacodynamic (PD) Parameters, and Multiple Sclerosis (MS) Disease Stability. | Berkovich, Regina MD, PhD Inc. | - Regina Berkovich MD, PhD Inc., West Hollywood, California, United States, 90048
|
| 207 | An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis | Hoffmann-La Roche | - Loma Linda University health, Loma Linda, California, United States, 92354
- University of California San Francisco, San Francisco, California, United States, 94117
|
| 208 | A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo | Mapi Pharma Ltd. | |
| 209 | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) | Celgene | |
| 210 | Decision Making Among Older Adults: the AUTO Study | University of Colorado, Denver | - University of California, San Diego, La Jolla, California, United States, 92037
|
| 211 | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis | ProgenaBiome | - ProgenaBiome, Ventura, California, United States, 93003
|
| 212 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | - Research Site 642, Long Beach, California, United States, 90806
- Research Site 644, Pasadena, California, United States, 91105
|
| 213 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | |
| 214 | A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy | Novartis Pharmaceuticals | - Novartis Investigative Site, Fullerton, California, United States, 92835
|
| 215 | An Open-Label, Multicenter Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab | Genentech, Inc. | - USC Keck School Of Medicine, Los Angeles, California, United States, 90033
|
| 216 | Monoclonal Antibodies in Mothers\' Milk and Infants: Ocrelizumab in Breastmilk | University of California, San Francisco | - University of California, San Francisco, San Francisco, California, United States, 94158
|
| 217 | Exploratory Study of Entire-body PET Scans for Multiple Sclerosis | Brain Health Alliance | - Brain Health Alliance, Ladera Ranch, California, United States, 92694
|
| 218 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) | Sanofi | - Investigational Site Number 8400045, Long Beach, California, United States, 90806
- Investigational Site Number 8400088, Torrance, California, United States, 90502
|
| 219 | Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset | University of California, San Francisco | - University of California San Francisco, San Francisco, California, United States, 94158
|
| 220 | Effects of Non-invasive Transcranial Electrical Stimulation on Cognition in Patients With Multiple Sclerosis | University of California, San Francisco | - UCSF Sandler Neurosciences Center, San Francisco, California, United States, 94158
|
| 221 | Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis | The Cleveland Clinic | - Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
- University of Southern California, Los Angeles, California, United States, 90089
|
| 222 | A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis | Hoffmann-La Roche | |
| 223 | A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | Hoffmann-La Roche | |
| 224 | BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia | Leigh R. Hochberg, MD, PhD. | - Stanford University School of Medicine, Stanford, California, United States, 94305
|
| 225 | Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALS | University of Kansas Medical Center | - UC Irvine, Irvine, California, United States, 92868
|
| 226 | Phenotype, Genotype & Biomarkers in ALS and Related Disorders | University of Miami | - Stanford University, Palo Alto, California, United States, 94304
- University of California San Diego (UCSD), San Diego, California, United States, 92093
|
| 227 | Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2 | University of California, San Francisco | - University of California, Los Angeles, Los Angeles, California, United States, 90095
|
| 228 | A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation | Biogen | - University of California San Diego Medical Center, La Jolla, California, United States, 92093-0949
|
| 229 | Genomic Translation for Amyotrophic Lateral Sclerosis Care | Columbia University | - Cedar Sinai Medical Center, Los Angeles, California, United States, 90048
|
| 230 | Fluid Biomarkers With Deep Phenotyping in Patients With ALS | Barrow Neurological Institute | - University of California, Irvine, Dept. of Neurology, Orange, California, United States, 92868
|
| 231 | An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation | Biogen | - Research Site, La Jolla, California, United States, 92093-0949
|
| 232 | A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS | Brainstorm-Cell Therapeutics | - University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States, 92697
- Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
|
| 233 | Clinical Procedures to Support Research in ALS (CAPTURE-ALS) | University of Miami | - Stanford University, Palo Alto, California, United States, 94304
- California Pacific Medical Center, San Francisco, California, United States, 94115
|
| 234 | A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis | Orphazyme | |
| 235 | A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | Biogen | - Research Site, La Jolla, California, United States, 92037-0886
- Research Site, Los Angeles, California, United States, 90048
|
| 236 | Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial | Orphazyme | |
| 237 | A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With Amyotrophic Lateral Sclerosis | Biogen | - University of California San Diego Medical Center, San Diego, California, United States, 92121
|
| 238 | A Pilot Study to Assess Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx | Powell Mansfield Inc. | - SENTA Clinic, San Diego, California, United States, 92108
|
| 239 | A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis | MediciNova | - University of California, Orange, California, United States, 92868
|
| 240 | Oxidative Markers and Efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes Treated With Edaravone | Loma Linda University | - Loma Linda University, Loma Linda, California, United States, 92354
|
| 241 | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Amyotrophic Lateral Sclerosis | ProgenaBiome | - ProgenaBiome, Ventura, California, United States, 93003
|
| 242 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS) | Alexion Pharmaceuticals | |
| 243 | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) | Mitsubishi Tanabe Pharma America Inc. | |
| 244 | An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | Biogen | - Research Site, La Jolla, California, United States, 92037-0886
- Research Site, Palo Alto, California, United States, 94304
|
| 245 | HEALEY ALS Platform Trial | Merit E. Cudkowicz, MD | - Loma Linda University Health, Loma Linda, California, United States, 92354
|
| 246 | ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | Mayo Clinic | - University of California, Los Angeles, Los Angeles, California, United States, 90095
|
| 247 | A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Annexon, Inc. | - Annexon Investigational Site 01, Irvine, California, United States, 92868
|
| 248 | Adaptive
Neurostimulation to Restore Sleep in Parkinson's Disease: An Investigation of STN LFP Biomarkers in Sleep
Dysregulation and Repair | University of Nebraska | - Standord University Medical Center, Stanford, California, United States, 94305
|
| 249 | Auricular
Muscle Zone Stimulation for Parkinson Disease (Earstim-PD) | Stoparkinson Healthcare Systems LLC | - University of Southern California, Los Angeles, California, United States, 90033
|
| 250 | A
Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety,
Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease
| UCB Biopharma SRL | - Pd0053 50385, Fresno, California, United States, 93710
|
| 251 | Adaptive
Cortical and Subcortical Brain Stimulation to Improve Motor Behaviors and Gait in Parkinson's Disease
| University of California, San Francisco | - UCSF, San Francisco, California, United States, 94134
|
| 252 | Cutaneous
Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy | CND Life Sciences | |
| 253 | Real-Time
Levodopa Monitoring for Improved Management of Parkinson Disease | University of California, San Diego | - University of California San DIego, San Diego, California, United States, 92093
|
| 254 | An
Open-Label Extension Of Study M15-736 To Evaluate The Safety And Tolerability Of 24-Hour Daily Exposure Of
ABBV-951 In Subjects With Advanced Parkinson's Disease | AbbVie | |
| 255 | A
Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and
Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | Hoffmann-La Roche | |
| 256 | Opicapone Treatment
Initiation Open-Label Study | Neurocrine Biosciences | - Neurocrine clinical site, Los Gatos, California, United States, 95032
|
| 257 | A
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety
of AL002 in Participants With Early Alzheimer's Disease | Alector Inc. | |
| 258 | Lifestyle Intervention
for Early Alzheimer's Disease | Preventive Medicine Research Institute | - Dean Ornish, M.D., Sausalito, California, United States, 94965
|
| 259 | A
Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and
Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
| Janssen Research & Development, LLC | |
| 260 | Extending
Independence and Quality of Life for People With Alzheimer's Disease or Dementia Through Telehealth Program
Delivery | University of California, San Francisco | - University of California, San Francisco, San Francisco, California, United States, 94143
|
| 261 | A
Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of
Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's
Disease | Washington University School of Medicine | - University of California San Diego Medical Center, La Jolla, California, United States, 92037
|
| 262 | Donanemab
Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of
Remote Neuropsychological Assessments | Eli Lilly and Company | |
| 263 | Evaluation
of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and
Acute Conditions | Thomas Advanced Medical LLC | - Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple
US-based Sub-Investigator Sites, Culver City, California, United States, 92032
|
| 264 | A
Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Assess the Efficacy and Safety of AXS-05
for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type | Axsome Therapeutics, Inc. | - Clinical Research Site, Los Alamitos, California, United States, 90720
- Clinical Research Site, Santa Ana, California, United States, 92705
|
| 265 | Computerized
Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease | Neurobehavioral Systems, Inc. | - Neurobehavioral Systems, Inc., Berkeley, California, United States, 94704
|
